Published in J Med Microbiol on July 01, 2007
Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol (2013) 2.89
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A (2010) 2.11
Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A (2010) 1.89
The human microbiome and its potential importance to pediatrics. Pediatrics (2012) 1.74
Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care (2014) 1.38
Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol (2011) 1.34
Therapeutic implications of manipulating and mining the microbiota. J Physiol (2009) 1.16
Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog (2009) 1.03
Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol (2016) 1.01
New advances in the treatment of Clostridium difficile infection (CDI). Ther Clin Risk Manag (2008) 0.98
The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria. BMC Microbiol (2013) 0.96
High-throughput sequence-based analysis of the intestinal microbiota of weanling pigs fed genetically modified MON810 maize expressing Bacillus thuringiensis Cry1Ab (Bt maize) for 31 days. Appl Environ Microbiol (2012) 0.90
The effect of feeding Bt MON810 maize to pigs for 110 days on intestinal microbiota. PLoS One (2012) 0.90
Bioengineering Lantibiotics for Therapeutic Success. Front Microbiol (2015) 0.86
Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol (2016) 0.86
Thusin, a Novel Two-Component Lantibiotic with Potent Antimicrobial Activity against Several Gram-Positive Pathogens. Front Microbiol (2016) 0.85
The multifaceted role of commensal microbiota in homeostasis and gastrointestinal diseases. J Immunol Res (2015) 0.84
The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes (2014) 0.84
Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models. Gastroenterol Res Pract (2015) 0.84
New horizons for host defense peptides and lantibiotics. Curr Opin Pharmacol (2012) 0.84
Assessing the contributions of the LiaS histidine kinase to the innate resistance of Listeria monocytogenes to nisin, cephalosporins, and disinfectants. Appl Environ Microbiol (2012) 0.83
99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: host-microbe interactions in the gut: target for drug therapy, opportunity for drug discovery. Clin Exp Immunol (2010) 0.83
Antimicrobial activity of lactic acid bacteria in dairy products and gut: effect on pathogens. Biomed Res Int (2015) 0.83
Probiotics against neoplastic transformation of gastric mucosa: effects on cell proliferation and polyamine metabolism. World J Gastroenterol (2014) 0.82
The Lantibiotic Lacticin 3147 Prevents Systemic Spread of Staphylococcus aureus in a Murine Infection Model. Int J Microbiol (2012) 0.81
Intraguild predation provides a selection mechanism for bacterial antagonistic compounds. Proc Biol Sci (2012) 0.80
Pseudomycoicidin, a Class II Lantibiotic from Bacillus pseudomycoides. Appl Environ Microbiol (2015) 0.79
A conserved streptococcal membrane protein, LsrS, exhibits a receptor-like function for lantibiotics. J Bacteriol (2014) 0.79
Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev (2017) 0.78
Fate of the two-component lantibiotic lacticin 3147 in the gastrointestinal tract. Appl Environ Microbiol (2007) 0.78
Sequence-based analysis of the intestinal Microbiota of sows and their offspring fed genetically modified maize expressing a truncated form of Bacillus thuringiensis Cry1Ab protein (Bt Maize). Appl Environ Microbiol (2013) 0.77
On Lactococcus lactis UL719 competitivity and nisin (Nisaplin(®)) capacity to inhibit Clostridium difficile in a model of human colon. Front Microbiol (2015) 0.77
The Microbiota and Health Promoting Characteristics of the Fermented Beverage Kefir. Front Microbiol (2016) 0.77
Survival and Metabolic Activity of Pediocin Producer Pediococcus acidilactici UL5: Its Impact on Intestinal Microbiota and Listeria monocytogenes in a Model of the Human Terminal Ileum. Microb Ecol (2015) 0.77
Inactivation Strategies for Clostridium perfringens Spores and Vegetative Cells. Appl Environ Microbiol (2016) 0.75
Heterologous expression of thuricin CD immunity genes in Listeria monocytogenes. Antimicrob Agents Chemother (2014) 0.75
Association of tcdA+/tcdB+ Clostridium difficile Genotype with Emergence of Multidrug-Resistant Strains Conferring Metronidazole Resistant Phenotype. Iran Biomed J (2015) 0.75
Microbiome: Paediatricians' perspective. Indian J Med Res (2015) 0.75
Advances in the Microbiome: Applications to Clostridium difficile Infection. J Clin Med (2016) 0.75
Lactolisterin BU, a novel Class II broad spectrum bacteriocin from Lactococcus lactis subsp. lactis bv. diacetylactis BGBU1-4. Appl Environ Microbiol (2017) 0.75
Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective. Front Microbiol (2017) 0.75
The gut flora as a forgotten organ. EMBO Rep (2006) 7.42
Gut microbiota composition correlates with diet and health in the elderly. Nature (2012) 6.94
Bacteriocins: developing innate immunity for food. Nat Rev Microbiol (2005) 5.77
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology (2005) 5.75
Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep (2013) 5.38
Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A (2010) 5.02
Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One (2009) 4.93
Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol (2010) 4.45
Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions. Nucleic Acids Res (2010) 4.17
The interaction between bacteria and bile. FEMS Microbiol Rev (2005) 3.86
Surviving the acid test: responses of gram-positive bacteria to low pH. Microbiol Mol Biol Rev (2003) 3.54
Bacterial osmoadaptation: the role of osmolytes in bacterial stress and virulence. FEMS Microbiol Rev (2002) 3.40
Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A (2007) 3.32
Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev (2010) 3.30
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol (2006) 3.24
Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol (2006) 2.93
Bacteriocins - a viable alternative to antibiotics? Nat Rev Microbiol (2012) 2.76
Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A (2008) 2.53
The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol (2006) 2.53
Multireplicon genome architecture of Lactobacillus salivarius. Proc Natl Acad Sci U S A (2006) 2.43
Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl Environ Microbiol (2009) 2.34
Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology (2006) 2.28
Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut (2012) 2.24
Functional genome analysis of Bifidobacterium breve UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. Proc Natl Acad Sci U S A (2011) 2.22
Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci (2005) 2.21
Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog (2008) 2.21
Bile salt hydrolase activity in probiotics. Appl Environ Microbiol (2006) 2.19
The role of substance P in inflammatory disease. J Cell Physiol (2004) 2.19
Genome sequence of Lactobacillus helveticus, an organism distinguished by selective gene loss and insertion sequence element expansion. J Bacteriol (2007) 2.15
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A (2010) 2.11
Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci U S A (2012) 2.09
Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol (2002) 2.07
Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol (2010) 2.02
Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res (2007) 1.99
Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology (2011) 1.96
The interplay between classical and alternative isoprenoid biosynthesis controls gammadelta T cell bioactivity of Listeria monocytogenes. FEBS Lett (2004) 1.93
Contribution of three bile-associated loci, bsh, pva, and btlB, to gastrointestinal persistence and bile tolerance of Listeria monocytogenes. Infect Immun (2005) 1.90
Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A (2010) 1.89
Tools for functional postgenomic analysis of listeria monocytogenes. Appl Environ Microbiol (2008) 1.78
A PrfA-regulated bile exclusion system (BilE) is a novel virulence factor in Listeria monocytogenes. Mol Microbiol (2005) 1.74
Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology (2006) 1.73
The mycobacteria story in Crohn's disease. Am J Gastroenterol (2005) 1.71
High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother (2012) 1.69
Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl Environ Microbiol (2009) 1.68
Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis (2013) 1.63
The generation of nisin variants with enhanced activity against specific gram-positive pathogens. Mol Microbiol (2008) 1.62
Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry (2004) 1.61
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio (2012) 1.59
Bacteriocin production: a probiotic trait? Appl Environ Microbiol (2011) 1.57
Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol (2008) 1.56
Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut (2008) 1.54
Improved luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro. Appl Environ Microbiol (2007) 1.54
Celiac disease and the transition from childhood to adulthood: a 28-year follow-up. Am J Gastroenterol (2004) 1.53
Listeriolysin S, a novel peptide haemolysin associated with a subset of lineage I Listeria monocytogenes. PLoS Pathog (2008) 1.53
The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes (2012) 1.52
Novel luciferase reporter system for in vitro and organ-specific monitoring of differential gene expression in Listeria monocytogenes. Appl Environ Microbiol (2006) 1.50
Radiologic imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades. Chest (2011) 1.49
Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev (2009) 1.48
Radiation exposure from diagnostic imaging among patients with gastrointestinal disorders. Clin Gastroenterol Hepatol (2011) 1.48
Programming infant gut microbiota: influence of dietary and environmental factors. Curr Opin Biotechnol (2010) 1.48
Human neutrophil clearance of bacterial pathogens triggers anti-microbial γδ T cell responses in early infection. PLoS Pathog (2011) 1.46
Bile stress response in Listeria monocytogenes LO28: adaptation, cross-protection, and identification of genetic loci involved in bile resistance. Appl Environ Microbiol (2002) 1.46
Multiple deletions of the osmolyte transporters BetL, Gbu, and OpuC of Listeria monocytogenes affect virulence and growth at high osmolarity. Appl Environ Microbiol (2002) 1.46
Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol Microbiol (2006) 1.45
Microbiomic analysis of the bifidobacterial population in the human distal gut. ISME J (2009) 1.43
Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol (2008) 1.42
Streptolysin S-like virulence factors: the continuing sagA. Nat Rev Microbiol (2011) 1.42
The LisRK signal transduction system determines the sensitivity of Listeria monocytogenes to nisin and cephalosporins. Antimicrob Agents Chemother (2002) 1.41
World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol (2012) 1.39
A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci (2009) 1.39
A five-strain probiotic combination reduces pathogen shedding and alleviates disease signs in pigs challenged with Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol (2007) 1.38